TY  - JOUR
AU  - Marks, Victoria A
AU  - Hsiang, Walter R
AU  - Nie, James
AU  - Umer, Waez
AU  - Haleem, Afash
AU  - Galal, Bayan
AU  - Pak, Irene
AU  - Kim, Dana
AU  - Salazar, Michelle C
AU  - Pantel, Haddon
AU  - Berger, Elizabeth R
AU  - Boffa, Daniel J
AU  - Cavallo, Jaime A
AU  - Leapman, Michael S
PY  - 2023
DA  - 2023/11/2
TI  - Telehealth Availability for Cancer Care During the COVID-19 Pandemic: Cross-Sectional Study
JO  - JMIR Cancer
SP  - e45518
VL  - 9
KW  - telehealth
KW  - colorectal cancer
KW  - breast cancer
KW  - melanoma
KW  - access to care
KW  - COVID-19 pandemic
KW  - telemedicine
KW  - national survey
KW  - cross-sectional
KW  - cancer
KW  - oncology
AB  - Background: Telehealth was an important strategy for maintaining continuity of cancer care during the coronavirus pandemic and has continued to play a role in outpatient care; however, it is unknown whether services are equally available across cancer hospitals. Objective: This study aimed to assess telehealth availability at cancer hospitals for new and established patients with common cancers to contextualize the impact of access barriers to technology on overall access to health care. Methods: We conducted a national cross-sectional secret shopper study from June to November 2020 to assess telehealth availability at cancer hospitals for new and established patients with colorectal, breast, and skin (melanoma) cancer. We examined facility-level factors to determine predictors of telehealth availability. Results: Of the 312 investigated facilities, 97.1% (n=303) provided telehealth services for at least 1 cancer site. Telehealth was less available to new compared to established patients (n=226, 72% vs n=301, 97.1%). The surveyed cancer hospitals more commonly offered telehealth visits for breast cancer care (n=266, 85%) and provided lower access to telehealth for skin (melanoma) cancer care (n=231, 74%). Most hospitals (n=163, 52%) offered telehealth for all 3 cancer types. Telehealth availability was weakly correlated across cancer types within a given facility for new (r=0.16, 95% CI 0.09-0.23) and established (r=0.14, 95% CI 0.08-0.21) patients. Telehealth was more commonly available for new patients at National Cancer Institute–designated facilities, medical school–affiliated facilities, and major teaching sites, with high total admissions and below-average timeliness of care. Telehealth availability for established patients was highest at Academic Comprehensive Cancer Programs, nongovernment and nonprofit facilities, medical school–affiliated facilities, Accountable Care Organizations, and facilities with a high number of total admissions. Conclusions: Despite an increase in telehealth services for patients with cancer during the COVID-19 pandemic, we identified differences in access across cancer hospitals, which may relate to measures of clinical volume, affiliation, and infrastructure. 
SN  - 2369-1999
UR  - https://cancer.jmir.org/2023/1/e45518
UR  - https://doi.org/10.2196/45518
UR  - http://www.ncbi.nlm.nih.gov/pubmed/37917149
DO  - 10.2196/45518
ID  - info:doi/10.2196/45518
ER  -